N4-Cyclopropyl-N2-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine

ID: ALA4758769

PubChem CID: 118906124

Max Phase: Preclinical

Molecular Formula: C17H17F3N4O2

Molecular Weight: 366.34

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  FC(F)(F)c1cnc(Nc2ccc3c(c2)OCCCO3)nc1NC1CC1

Standard InChI:  InChI=1S/C17H17F3N4O2/c18-17(19,20)12-9-21-16(24-15(12)22-10-2-3-10)23-11-4-5-13-14(8-11)26-7-1-6-25-13/h4-5,8-10H,1-3,6-7H2,(H2,21,22,23,24)

Standard InChI Key:  KDBZMDYBJJGQDJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
   12.6114  -18.0360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6102  -18.8555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3183  -19.2645    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.0280  -18.8550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0251  -18.0324    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.3165  -17.6271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9036  -17.6275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9034  -16.8103    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.1960  -18.0363    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.1930  -17.2188    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.9022  -19.2635    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7363  -19.2625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7376  -20.0797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0292  -20.4878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0301  -21.3043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4440  -20.4834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9016  -20.0807    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4933  -20.7904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3105  -20.7910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7416  -21.7153    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4491  -21.2945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2257  -21.5847    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.6307  -22.5368    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.4849  -22.3687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2041  -23.1347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0285  -23.0570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  1  7  1  0
  7  8  1  0
  7  9  1  0
  7 10  1  0
  2 11  1  0
  4 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 20  2  0
 21 16  2  0
 16 13  1  0
 11 17  1  0
 18 17  1  0
 19 18  1  0
 17 19  1  0
 20 21  1  0
 21 22  1  0
 20 23  1  0
 22 24  1  0
 23 25  1  0
 24 26  1  0
 25 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4758769

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 366.34

Molecular Weight (Monoisotopic): 366.1304

AlogP: 3.97

#Rotatable Bonds: 4

Polar Surface Area: 68.30

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.95

CX Basic pKa: 4.31

CX LogP: 3.15

CX LogD: 3.15

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.85

Np Likeness Score: -1.40

References

1. Ren H,Bakas NA,Vamos M,Chaikuad A,Limpert AS,Wimer CD,Brun SN,Lambert LJ,Tautz L,Celeridad M,Sheffler DJ,Knapp S,Shaw RJ,Cosford NDP.  (2020)  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.,  63  (23): [PMID:33200929] [10.1021/acs.jmedchem.0c00873]

Source

Source(1):

• Scientific Literature